- Home
- MGNX vs MHH Comparison
MGNX vs MHH Comparison
Compare MGNX & MHH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MGNX
- MHH
- Stock Information
- Founded
- MGNX 2000
- MHH 1986
- Country
- MGNX United States
- MHH United States
- Employees
- MGNX N/A
- MHH N/A
- Industry
- MGNX Biotechnology: Pharmaceutical Preparations
- MHH Professional Services
- Sector
- MGNX Health Care
- MHH Consumer Discretionary
- Exchange
- MGNX Nasdaq
- MHH Nasdaq
- Market Cap
- MGNX 202.7M
- MHH 163.5M
- IPO Year
- MGNX 2013
- MHH N/A
- Fundamental
- Price
- MGNX $2.86
- MHH $13.74
- Analyst Decision
- MGNX Hold
- MHH
- Analyst Count
- MGNX 10
- MHH 0
- Target Price
- MGNX $7.17
- MHH N/A
- AVG Volume (30 Days)
- MGNX 642.4K
- MHH 24.3K
- Earning Date
- MGNX 03-06-2025
- MHH 02-14-2025
- Dividend Yield
- MGNX N/A
- MHH N/A
- EPS Growth
- MGNX N/A
- MHH N/A
- EPS
- MGNX N/A
- MHH N/A
- Revenue
- MGNX $141,329,000.00
- MHH $194,248,000.00
- Revenue This Year
- MGNX $174.73
- MHH $0.53
- Revenue Next Year
- MGNX N/A
- MHH $1.53
- P/E Ratio
- MGNX N/A
- MHH N/A
- Revenue Growth
- MGNX 16.68
- MHH N/A
- 52 Week Low
- MGNX $2.79
- MHH $7.15
- 52 Week High
- MGNX $21.88
- MHH $16.00
- Technical
- Relative Strength Index (RSI)
- MGNX 34.55
- MHH 43.50
- Support Level
- MGNX $2.93
- MHH $13.11
- Resistance Level
- MGNX $3.16
- MHH $14.75
- Average True Range (ATR)
- MGNX 0.18
- MHH 0.84
- MACD
- MGNX -0.02
- MHH -0.12
- Stochastic Oscillator
- MGNX 1.90
- MHH 8.30
About MGNX MacroGenics Inc.
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. Its pipeline MGC018 (B7-H3), Lorigerlimab (PD-1 x CTLA-4), Tebotelimab (PD-1 x LAG-3), MGD024 (CD123 x CD3), IMGC936 (ADAM9), Enoblituzumab (anti-B7-H3), Retifanlimab (PD-1), and MGD014 (HIV x CD3).
About MHH Mastech Digital Inc
Mastech Digital Inc is a provider of Digital Transformation IT Services. The Company offers data & analytics solutions & IT staffing services for both digital & mainstream technologies. The Group has two segments. Its Data & Analytics Services segment delivers specialized data management, data engineering, customer experience consulting, data analytics & cloud services to customers globally. IT Staffing Services segment combines technical expertise with business process experience to deliver a broad range of services in digital & mainstream technologies. The company derives a majority of its revenue from IT staffing services. Geographically, the majority of revenue is generated from the United States.